Classification of bioactive substances in SBS. حسب Minghui Zhang (298745)

"…The results showed that: (1) Compared with the CON group, the dressing percentage and eye muscle area in the SBS24 group significantly increased (<i>P</i> < 0.05); (2) Compared with the CON group, the butyrate content and total fatty acid content inthe SBS24 group significantly increased (<i>P</i> < 0.05); (3) Compared with the CON group, the Simpson index of the SBS groups significantly increased (<i>P</i> < 0.05), while the Shannon index of the SBS12, SBS18, and SBS24 groups significantly decreased (<i>P</i> < 0.01). …"

OTU venn diagram. حسب Minghui Zhang (298745)

"…The results showed that: (1) Compared with the CON group, the dressing percentage and eye muscle area in the SBS24 group significantly increased (<i>P</i> < 0.05); (2) Compared with the CON group, the butyrate content and total fatty acid content inthe SBS24 group significantly increased (<i>P</i> < 0.05); (3) Compared with the CON group, the Simpson index of the SBS groups significantly increased (<i>P</i> < 0.05), while the Shannon index of the SBS12, SBS18, and SBS24 groups significantly decreased (<i>P</i> < 0.01). …"

PCR reaction system. حسب Minghui Zhang (298745)

"…The results showed that: (1) Compared with the CON group, the dressing percentage and eye muscle area in the SBS24 group significantly increased (<i>P</i> < 0.05); (2) Compared with the CON group, the butyrate content and total fatty acid content inthe SBS24 group significantly increased (<i>P</i> < 0.05); (3) Compared with the CON group, the Simpson index of the SBS groups significantly increased (<i>P</i> < 0.05), while the Shannon index of the SBS12, SBS18, and SBS24 groups significantly decreased (<i>P</i> < 0.01). …"

Nutritional composition of SBS (DM basis, %). حسب Minghui Zhang (298745)

"…The results showed that: (1) Compared with the CON group, the dressing percentage and eye muscle area in the SBS24 group significantly increased (<i>P</i> < 0.05); (2) Compared with the CON group, the butyrate content and total fatty acid content inthe SBS24 group significantly increased (<i>P</i> < 0.05); (3) Compared with the CON group, the Simpson index of the SBS groups significantly increased (<i>P</i> < 0.05), while the Shannon index of the SBS12, SBS18, and SBS24 groups significantly decreased (<i>P</i> < 0.01). …"

The impact of nano-curcumin on cell viability and proliferation in breast cancer cells. حسب Taraneh Givi (22793530)

Included studies basic characteristics. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for FVC. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

All data extracted. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for TNF- حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Bias risk assessment of included studies. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for hs-CRP. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for IL-6. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

The incidence rate of adverse reactions. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

The PRISMA study flowchart. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for FEV1/FVC. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for clinical efficacy. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for FEV1. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

The excluded and included studies were listed. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for PaCO₂. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"

Forest plot for PaO₂. حسب Xuqin Du (8803772)

"…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …"